Low-Dose Naltrexone Hair and Skin Changes: What the Evidence Actually Shows

What low-dose naltrexone is

LDN means naltrexone at doses far below the approved 50 mg tablet, typically 0.5 to 6 mg a day and most often 4.5 mg, used off-label and supplied mainly through compounding pharmacies [1]. A 2026 narrative review calls the 4.5 mg dose empirically derived rather than evidence-based and describes the proposed TLR4, opioid-receptor and opioid growth factor mechanisms as largely theoretical and speculative [1]. FDA states that compounded drugs are not FDA-approved and that it does not verify their safety, effectiveness or quality before they are marketed [3].

Does it help hair or skin conditions?

No LDN product or LDN indication is FDA-approved. A 2026 review screened 105 LDN studies, 15 of them randomized trials across areas that included dermatological conditions. It found that early positive results from uncontrolled studies were rarely reproduced in placebo-controlled trials, and that most evidence is case reports and small feasibility studies prone to publication bias [1].

Fibromyalgia, a heavily studied LDN condition, shows the pattern. An early crossover trial in 31 women reported pain 28.8% lower on 4.5 mg versus 18.0% on placebo [5], while later placebo-controlled trials in 58, 98 and 99 patients did not beat placebo on their main pain outcomes [6][7][8]. A 2018 review lists Hailey-Hailey disease among conditions with clinical reports of possible benefit; those are reports, not controlled trials [9].

What the 50 mg label says about hair and skin

The naltrexone hydrochloride tablet label lists oily skin, pruritus, acne, athlete's foot, cold sores and alopecia among events that occurred in less than 1% of subjects in its opioid-addiction trials [2]. The label also says naltrexone has not been shown to cause significant increases in complaints in placebo-controlled trials in patients known to be opioid-free for more than 7 to 10 days [2]. Those events were reported with the approved tablet in people with opioid dependence, not with compounded LDN, and the label is written for alcohol dependence and opioid blockade with no dosing guidance for LDN [2][1]. LDN trials most often report insomnia, vivid dreams, nausea and dizziness, usually mild and transient [1].

Itch and safety points

Skin evidence for this drug class that does exist concerns itch, and it is not LDN-specific: a 2010 review found significant antipruritic relief in double-blind studies of cholestatic pruritus, chronic urticaria and atopic dermatitis with systemic mu-opioid antagonists including naloxone, nalmefene and naltrexone, while calling most of the evidence anecdotal [10].

For the approved 50 mg tablet and the 380 mg injection, the labels recommend a minimum 7-to-10-day opioid-free interval before starting [2][4]. The tablet label adds that people switching from buprenorphine or methadone may remain vulnerable to precipitated withdrawal for as long as 2 weeks [2]. Both labels list contraindications for patients receiving opioid analgesics and for patients currently dependent on opioids, and neither gives LDN dosing guidance or a dose exception [2][4][1]. Hepatotoxicity sits in the Warnings section rather than a boxed warning, and the tablet label describes hepatocellular injury in placebo-controlled studies at up to 300 mg a day, five times the recommended dose [2][4].